Clinical Guides
Age-Related Macular Degeneration
A clinically focused guide to recognising, investigating and managing age-related macular degeneration in India, with urgent pathways for suspected neovascular disease, realistic treatment limits, visual rehabilitation and explicit safeguards against delaying specialist retinal assessment.
MedNext Academy | 13 min read
Age-Related Macular Degeneration
A clinically focused guide to recognising, investigating and managing age-related macular degeneration in India, with urgent pathways for suspected neovascular disease, realistic treatment limits, visual rehabilitation and explicit safeguards against delaying specialist retinal assessment.
Summary
Age-related macular degeneration (AMD) is a degenerative disorder of the central retina in later life. It damages the macula and therefore threatens reading, face recognition, colour discrimination and other detailed vision, while peripheral vision is usually retained. Early AMD is characterised by drusen and pigmentary change. Late disease comprises neovascular, or wet, AMD and geographic atrophy, an advanced atrophic form. The distinction matters: neovascular AMD can worsen rapidly but may respond to intravitreal vascular endothelial growth factor (VEGF) inhibition; atrophy usually progresses more slowly and has no routinely available restorative treatment in India.
New distortion, a central grey patch or sudden unexplained central visual decline in an older adult should be treated as suspected neovascular AMD until a retinal assessment excludes it. Check each eye separately, assess visual acuity and use an Amsler grid only as an adjunct. Dilated macular examination and optical coherence tomography (OCT) are central to diagnosis. Fundus fluorescein angiography is added when OCT does not exclude neovascular disease or when lesion anatomy remains uncertain.
Management includes smoking cessation, control of vascular risk for general health, selected AREDS2-type supplementation only for appropriate stages after clinician review, anti-VEGF treatment for active neovascular disease, and early low-vision support. Supplements do not prevent all AMD or restore lost sight. This educational draft is not a prescription, has been reviewed by the MedNext Clinical Team and must not delay urgent ophthalmic referral.
How Common Is It?
AMD is an important cause of irreversible central visual impairment among older adults worldwide. Its frequency rises steeply with age, but reported prevalence differs with the population sampled, retinal photography protocol, grading system and definition of early or late disease. Indian estimates are heterogeneous because rural and urban cohorts, access to retinal imaging, survival and risk-factor patterns differ. A single prevalence percentage should therefore not be transferred to every Indian clinic or used to predict an individual's outcome.
The public-health burden extends beyond measured visual acuity. Bilateral central field loss can impair reading medicines, recognising faces, handling money, cooking, driving and avoiding falls. Depression, social isolation and loss of independence may follow. One eye can compensate for the other until disease becomes bilateral, so asking about each eye separately is essential. Cataract may coexist and obscure the contribution of macular disease; surgery can improve media opacity but cannot reverse retinal damage.
Early changes are more common than late AMD, and only a subset progresses. Large drusen, pigment abnormalities, advanced disease in the fellow eye and smoking increase progression risk. Neovascular disease accounts for a disproportionate share of rapid severe central loss because leakage, haemorrhage and fibrosis can develop over weeks. Geographic atrophy causes enlarging areas of photoreceptor and retinal pigment epithelium loss. Service planning in India must consider retinal-imaging capacity, repeated injection visits, transport and low-vision availability, not merely the number diagnosed.
Risk Factors
Age is the strongest risk factor, and genetic susceptibility involving complement and lipid pathways contributes substantially. A family history of late AMD raises concern but does not determine destiny, and routine consumer genetic testing does not replace retinal examination. Cigarette smoking is the most important modifiable association; document current and past smoking, offer cessation support and avoid beta-carotene-containing supplements in current or former smokers because of lung-cancer risk. Diets rich in leafy vegetables, fruit and fish are reasonable for general health, but food advice should not be presented as a guaranteed treatment.
Ocular predictors of progression include large or numerous drusen, retinal pigment abnormalities, reticular pseudodrusen and late AMD in the fellow eye. High-risk findings require education about symptoms and follow-up appropriate to stage. Cardiovascular risk factors, including hypertension, dyslipidaemia and obesity, are associated variably across studies; manage them for established systemic benefit without promising that control will halt AMD. Excessive unprotected sunlight exposure is biologically plausible but evidence for a direct preventive effect of sunglasses is less certain than the evidence for smoking cessation.
History should include previous retinal treatment, adherence, anticoagulant or antiplatelet therapy, mobility, cognition and the practical ability to attend repeated visits. Antithrombotic medicines may influence haemorrhage appearance but should never be stopped without the prescriber's input. Poor access is a risk to vision after diagnosis: missed monitoring can allow silent or recurrent activity. In India, distance from a retina service, injection cost, need for an escort and fragmented records can be as consequential as biological risk and should be assessed explicitly.
Diagnosis
History
Ask about onset, tempo, laterality and the exact visual task affected. Metamorphopsia, in which straight lines appear bent, new central blur, a scotoma, reduced contrast or difficulty recognising faces supports macular dysfunction. Sudden or subacute change over days to weeks raises suspicion of neovascular conversion. Test each eye separately because binocular viewing masks unilateral decline. Record smoking, family history, previous drusen or AMD, prior injections, cataract, diabetes and medicines. Pain, marked redness or neurological symptoms are not typical and broaden the emergency differential.
Examination
Measure monocular best available distance and near acuity; acuity alone does not stage AMD. Check pupils, colour and confrontation fields when another optic-nerve or neurological process is possible. An Amsler grid can demonstrate distortion but a normal result does not exclude disease. Dilate when safe and examine the macula for drusen, pigment disturbance, subretinal fluid, haemorrhage, exudate, geographic atrophy or fibrosis. Document the fellow eye and assess media opacity, pressure and other retinal disease.
Investigations
Macular OCT is the key non-invasive investigation for suspected neovascular activity, showing intraretinal or subretinal fluid, pigment epithelial detachment and structural loss. Current guidelines recommends OCT in suspected late wet AMD and fundus fluorescein angiography when neovascular disease is not excluded by OCT alone. OCT angiography, indocyanine green angiography, fundus autofluorescence and colour photography answer selected questions but do not automatically replace clinical examination or fluorescein angiography. Imaging interpretation belongs within a retinal pathway because artefact, chronic cavities and non-AMD neovascularisation can mislead. Do not delay urgent referral while arranging non-essential tests in primary care.
Differential Diagnosis
Central visual loss in an older adult is not synonymous with AMD. Diabetic macular oedema, retinal vein occlusion and hypertensive macular change may produce fluid or haemorrhage; systemic history and the retinal vascular pattern help distinguish them. Epiretinal membrane and vitreomacular traction cause distortion with characteristic interface findings on OCT. A full-thickness macular hole produces central loss and a discrete foveal defect. Central serous chorioretinopathy, inflammatory choroidal neovascularisation and myopic neovascularisation can resemble wet AMD but occur in different clinical contexts and require different reasoning.
Polypoidal choroidal vasculopathy is particularly relevant in Asian populations and may present with recurrent subretinal haemorrhage or pigment epithelial detachments; indocyanine green angiography can clarify selected cases. Macular telangiectasia type 2, inherited macular dystrophies and medication toxicity should be considered when age, symmetry or morphology is atypical. Geographic atrophy must be differentiated from inherited or toxic retinal atrophy. A retinal specialist integrates both eyes, multimodal imaging and treatment response rather than assigning every druse-related change to one mechanism.
Cataract causes gradual blur and glare but not retinal fluid or a central retinal haemorrhage. Glaucoma usually affects field before central acuity, while optic neuropathy may cause dyschromatopsia and a relative afferent pupillary defect. Occipital stroke can produce a homonymous defect and associated neurological features. Acute retinal arterial occlusion, retinal detachment and vitreous haemorrhage are emergency causes of sudden loss. The diagnostic task is to identify treatable neovascular activity promptly while recognising coexisting disease that changes prognosis and rehabilitation.
Management
Explain the stage, which eye is affected, the expected course and which symptoms require urgent re-contact. For early AMD, focus on smoking cessation, balanced nutrition, optical correction and scheduled review according to risk. Routine high-dose antioxidant supplementation is not justified for people without the AREDS risk profile. For intermediate AMD or advanced AMD in one eye, an AREDS2 formulation may reduce progression to late disease in selected patients; it does not restore vision, prevent every conversion or substitute for monitoring. Review renal disease, interactions, smoking history and the exact product before use.
Active neovascular AMD is treated primarily with intravitreal anti-VEGF therapy. The retinal service selects the agent and regimen using lesion activity, visual potential, fellow-eye status, safety, availability and affordability. Loading, treat-and-extend, pro re nata and fixed strategies require reliable OCT-led surveillance; they are not interchangeable instructions for self-management. Delayed initiation or repeated missed visits can permit fibrosis and irreversible loss. Photodynamic therapy has a limited role in particular lesion phenotypes, sometimes with anti-VEGF therapy, rather than being routine first-line monotherapy.
For geographic atrophy, protect remaining function, optimise lighting and contrast, address smoking and refer early for low-vision rehabilitation. Some complement inhibitors are authorised in selected jurisdictions, but availability, indication, effect size, injection burden and adverse events must be checked locally; this guide does not assume Indian approval or recommend importation. Low-vision aids, electronic magnification, orientation training and certification for disability support can be valuable at any stage. Screen for falls risk and mood symptoms. Management is longitudinal and includes the fellow eye, not a one-time injection decision.
Prescribing Information
Intravitreal anti-VEGF medicines are specialist-administered products, not routine outpatient prescriptions. A retina clinician must verify the indication, eye, product, dose, interval, consent, ocular infection status, recent procedures and systemic history under the current Indian product label and institutional protocol. Do not infer a product substitution, interval change, compounding standard or off-label use from a general guide; these decisions require transparent local governance and patient-specific consent.
Important injection and agent-specific risks must be discussed using the verified current label and service protocol. The treating team should screen for active periocular infection and other exclusion criteria, use an aseptic intravitreal procedure, and provide a clear post-injection safety net. Increasing pain, redness, photophobia or deteriorating vision after injection requires immediate ophthalmic assessment. A general guide must not prescribe topical antibiotic prophylaxis, an injection schedule or a drug-specific risk-management plan.
AREDS2-type supplements generally combine antioxidant vitamins, zinc, copper, lutein and zeaxanthin. Products differ, and high-dose components can cause adverse effects or interact with illness and medicines. Beta-carotene should be avoided in current and former smokers. Supplementation is stage-specific, not a universal prevention pill. Record all non-prescription products. Lubricants may improve coexisting dry-eye symptoms but do not treat the macula. No eye drop, herbal product or oral medicine has been established to dissolve drusen or reverse geographic atrophy; claims of cure should trigger caution and a proper retinal review.
When to Refer
Suspected new neovascular AMD requires urgent referral through a pathway capable of retinal imaging and treatment. Current guidelines advises referral to a macular service normally within one working day when late wet AMD is suspected; in practice, sudden new distortion, central scotoma, subretinal haemorrhage or OCT fluid should be escalated the same day so assessment is not lost to routine booking. Do not wait for a community OCT, angiogram or trial of vitamins if those steps delay the retina service. Record onset, affected eye, acuity in each eye and relevant examination findings.
Refer non-urgently but promptly for unexplained drusen with symptoms, suspected geographic atrophy, progressive reading difficulty, uncertain diagnosis or coexisting cataract that complicates attribution. A retinal opinion is appropriate when OCT findings are atypical, haemorrhage is extensive, polypoidal disease is possible or response to treatment is incomplete. Established anti-VEGF patients with new symptoms, missed visits or recurrent activity need direct contact with their treating service rather than a new generic referral.
Low-vision referral should not wait until all treatment has ended. Offer rehabilitation when central loss interferes with tasks, even if one eye retains useful acuity. In India, routes may include government medical colleges, district eye services, charitable hospitals and private retina centres; capacity for OCT, angiography and injections varies. Confirm where urgent patients will actually be seen, whether injections and follow-up are affordable, and how records will travel. Emergency referral is also required for severe pain, marked redness, a curtain-like field defect or neurological deficit because these are not routine AMD features.
Red Flags
The principal AMD red flag is new central visual distortion or loss, especially in an eye known to have drusen or when the fellow eye has late disease. Fresh subretinal or intraretinal haemorrhage, new fluid on OCT, a grey central patch or abrupt difficulty reading should trigger urgent neovascular assessment. A normal home Amsler grid, preserved Snellen acuity or absence of pain must not falsely reassure. Neovascular activity may begin between scheduled visits, and the treatment opportunity is time-sensitive because scarred photoreceptors cannot be recovered by later fluid control.
After an intravitreal injection, increasing ocular pain, redness, photophobia, discharge, hypopyon or worsening vision suggests endophthalmitis or severe inflammation and requires immediate ophthalmic review. A new field curtain, photopsia or numerous floaters suggests retinal tear or detachment. Sudden profound painless loss may indicate retinal vascular occlusion. Headache, jaw claudication, scalp tenderness or systemic malaise with acute visual symptoms raises concern for giant cell arteritis in an older adult and requires an emergency systemic pathway, not an AMD appointment.
Safeguarding and functional red flags include repeated falls, medication errors, inability to prepare food, hallucinations causing distress, depression and loss of independent living. Charles Bonnet visual hallucinations can occur with visual deprivation, but new confusion or neurological signs must not be attributed to them casually. Monocular patients need especially clear escalation instructions. Severe bilateral central loss should prompt rehabilitation, social-support assessment and driving advice. Any symptom pattern that is painful, very sudden, field-based or neurologically accompanied demands reconsideration of the diagnosis.
Indian Clinical Context
India has major geographic and financial variation in access to retinal specialists, OCT, fluorescein angiography and repeated intravitreal therapy. Primary eye-care guidance from the Ministry of Health and Family Welfare supports recognition, basic visual assessment and referral, but definitive AMD classification and anti-VEGF treatment require ophthalmic infrastructure. A written plan should specify the receiving facility, urgency, likely number of visits, cost discussions and whom to contact if vision changes. Merely advising follow-up without testing feasibility can produce preventable loss.
Polypoidal choroidal vasculopathy and large submacular haemorrhage deserve attention in Asian patients because imaging and management may differ from typical neovascular AMD. This does not justify ethnic stereotyping or routine expensive testing for everyone; it supports specialist multimodal imaging when morphology, haemorrhage or treatment response is atypical. Off-label intravitreal bevacizumab is used in many resource-constrained settings, but sterility, aliquoting, cold chain, informed consent and pharmacovigilance are essential. Cost saving is never a reason to accept unsafe compounding.
Home monitoring instructions should use the person's language, literacy and available technology. Teach separate-eye checking with a familiar reading target or grid and demonstrate what distortion means. Where smartphone monitoring is impractical, family support and scheduled examination are more realistic. Low-vision services, disability certification and assistive devices may be available through government, teaching, charitable or private systems but are unevenly distributed. current guidelines recommendations inform urgency and investigation here; they are not an Indian reimbursement rule. Every prescription and injection decision must follow current Indian regulation, formulary and local clinical governance.
NMC Competency Mapping
AMD learning aligns chiefly with OP8.3, which covers fundus examination and normal versus abnormal findings, and OP8.4, which covers treatment modalities for retinal disease. Supporting skills come from the visual-acuity and ocular-examination competencies. A student should take a focused history of central dysfunction, test each eye separately, measure distance and near acuity, recognise metamorphopsia, examine the macula under supervision and describe drusen, pigment change, haemorrhage and atrophy. The learner should distinguish early disease, geographic atrophy and neovascular AMD and explain why rapid change requires urgent retinal referral.
Diagnostic competence includes interpreting the purpose, not merely the appearance, of OCT and angiography. OCT identifies fluid and retinal structural change; fluorescein angiography clarifies leakage and lesion anatomy when OCT alone is insufficient. Students should integrate differential diagnoses such as diabetic macular oedema, vein occlusion, epiretinal membrane and macular hole. They must not perform invasive angiography or intravitreal injection without accredited training, supervision and local authorization. Reading this guide cannot certify procedural competence.
Therapeutic learning includes the mechanism and limitations of anti-VEGF therapy, injection complications, the restricted role of AREDS2 supplementation, smoking cessation and visual rehabilitation. Counselling should address chronic monitoring, recurrence, the fellow eye, realistic visual expectations and emergency post-injection symptoms. Indian systems learning includes referral across primary, district and tertiary eye services, treatment affordability and continuity. These objectives support CBME knowledge, clinical reasoning, communication and patient-safety domains; exact competency sign-off must use the current institutional NMC logbook and supervised assessment.
Key Exam Pearls for NEET PG
Drusen are extracellular deposits between the retinal pigment epithelium and Bruch membrane. Small hard drusen alone do not equal late AMD; large soft drusen and pigmentary disturbance indicate greater progression risk. Late AMD is either neovascular disease or geographic atrophy. Neovascularisation causes exudation, fluid, haemorrhage and eventually disciform scarring. Geographic atrophy produces sharply demarcated loss of retinal pigment epithelium and photoreceptors, often with visible choroidal vessels. Central detailed vision is affected while peripheral vision is relatively preserved.
Metamorphopsia is a classic symptom and an Amsler grid is a monitoring aid, not an exclusion test. OCT is first-line structural imaging for suspected activity. Fluorescein angiography is used when OCT does not exclude neovascularisation or lesion characterisation is required. Indocyanine green angiography helps identify polypoidal choroidal vasculopathy. Anti-VEGF injection is the main treatment for active neovascular AMD; response is monitored clinically and with OCT. New distortion warrants urgent macular-service referral rather than a routine optometry review.
AREDS2-type supplementation may reduce progression in selected people with intermediate AMD or advanced disease in one eye, but does not cure AMD. Lutein and zeaxanthin replaced beta-carotene in AREDS2 because beta-carotene is unsafe for smokers and former smokers. Smoking cessation is the clearest modifiable measure. Recognise endophthalmitis after injection: pain, redness and falling vision are an emergency. When no restorative treatment exists, low-vision rehabilitation remains active treatment, not therapeutic surrender. Exam answers should specify stage, eye and urgency rather than saying only 'macular degeneration'.
Frequently Asked Questions
Does new distortion in one eye need an urgent eye assessment?
Yes. New bending of straight lines, a central grey patch or subacute central visual decline can signal neovascular AMD. Check each eye separately and contact an urgent macular or retinal service; do not wait for a routine appointment, a vitamin trial or a community scan if those steps delay specialist assessment.
Do AREDS2 vitamins prevent or cure every case of macular degeneration?
No. An AREDS2-type formulation may reduce progression to late AMD for selected people at particular stages, but it does not restore lost retina or remove the need for monitoring. The exact product and suitability require clinician review, and beta-carotene-containing products should be avoided by current and former smokers.
Why are repeated OCT scans needed during anti-VEGF treatment?
Neovascular activity can recur without dramatic symptoms. OCT shows retinal or subretinal fluid and structural change that helps the retina clinician judge activity and treatment interval. It complements acuity and examination; apparent cavities, artefact and chronic damage must be interpreted clinically rather than treated automatically.
What help is available when AMD-related sight loss cannot be reversed?
Low-vision rehabilitation can improve function through optimized spectacles, lighting, contrast, magnification, electronic aids, orientation strategies and task-specific training. Assessment can also address falls, mood, hallucinations, disability support and family needs. Referral should begin when function is affected, not only after every retinal treatment has stopped.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic